Aligos Therapeutics presented 96-week data showing ALG-000184 achieved significant HBV DNA suppression in both HBeAg-positive and HBeAg-negative patients, positioning it as a potential first-line therapy for chronic hepatitis B.
Aligos Therapeutics has secured a $105 million private placement financing led by a life sciences investment firm, strengthening its position to advance ALG-000184 into Phase 2 clinical trials for chronic hepatitis B.
ALG-055009, a thyroid hormone receptor beta agonist, demonstrated statistically significant reductions in liver fat in a Phase 2a study for MASH, showing promise for MASH resolution and fibrosis improvement.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.